Assessing the eligibility of a breast cancer patient for genomic testing

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or unlikely to benefit from adjuvant chemotherapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, outlines the approaches for effectively communicating personalised genomic disease-risk information to breast cancer patients.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
03:15
Color/Sound

Comments are closed.